Menschen mit einem künstlichen Darmausgang waren bis zur Mitte des 20. Jahrhunderts nicht nur körperlich stark beeinträchtigt, sondern wurden wegen der schlechten medizinischen Versorgungsmöglichkeiten auch sozial ausgegrenzt. Die dänische Krankenschwester Elise Sørensen pflegte in den 1950er-Jahren solche Stomapatienten, deren Schicksale sie sehr berührten. Um die Lebensqualität der Betroffenen zu steigern, entwickelte Sørensen 1954 den weltweit ersten selbsthaftenden Einweg-Stomabeutel. Drei Jahre später wurde Coloplast A/V in Dänemark gegründet. Die Krankenschwester hatte den Ingenieur und Unternehmer Aage Louis-Hansen von den Marktchancen ihrer Innovation überzeugt.
Die Aktien von [b]Coloplast [/b]zählen zu den dänischen Perlen. Das Gesundheitsunternehmen besticht durch intakte Fundamentals und positive Zukunftsperspektiven. siehe payoff.ch
Coloplast launches new 2025 strategy and provides new long-term financial guidance of 7-9% organic revenue growth and an EBIT margin of more than 30%
Coloplast will host a virtual Capital Markets Day today at 14:00-17:00 (CET). Investors, analysts and journalists are invited to participate and the event can be accessed on the dedicated CMD microsite [u]here[/u].
As part of the Capital Markets Day 2020, Coloplast will launch its new 2025 strategy “Strive25 - Sustainable Growth Leadership”.
Strive25 long-term financial guidance
Coloplast remains committed to delivering strong revenue growth, industry-leading margins and strong cash flow generation. From the base year of 2019/20, Coloplast aims to deliver the following long-term financial ambitions:
Strive25 long-term non-financial ambitions
Coloplast has set the following sustainability and non-financial ambitions by 2025:
Reducing emissions
Financial guidance 2019/20
The financial guidance for 2019/20 is unchanged at an organic revenue growth of around 4% at constant exchange rates and a reported growth in DKK of 3-4%. The EBIT margin is expected to be around 31% at constant exchange rates and in reported terms in DKK.
2019/20 has seen a negative impact on the company’s financial performance from COVID-19. Throughout the pandemic, Coloplast has had three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations. globalnewswire
Die Aktien von [b]Coloplast [/b]zählen zu den dänischen Perlen. Das Gesundheitsunternehmen besticht durch intakte Fundamentals und positive Zukunftsperspektiven. siehe payoff.ch
Coloplast launches new 2025 strategy and provides new long-term financial guidance of 7-9% organic revenue growth and an EBIT margin of more than 30%
Coloplast will host a virtual Capital Markets Day today at 14:00-17:00 (CET). Investors, analysts and journalists are invited to participate and the event can be accessed on the dedicated CMD microsite [u]here[/u].
As part of the Capital Markets Day 2020, Coloplast will launch its new 2025 strategy “Strive25 - Sustainable Growth Leadership”.
Strive25 long-term financial guidance
Coloplast remains committed to delivering strong revenue growth, industry-leading margins and strong cash flow generation. From the base year of 2019/20, Coloplast aims to deliver the following long-term financial ambitions:
- Organic revenue growth of 7-9% p.a.
- EBIT margin of more than 30%1
- CAPEX ratio of 4-6% of revenue
- Tax rate of ~23%2
Strive25 long-term non-financial ambitions
Coloplast has set the following sustainability and non-financial ambitions by 2025:
Reducing emissions
- 0 scope 1+2 emissions through 100% renewable energy
- In 18/19, 7% of Coloplast’s total emissions was scope 1+2 emissions (equivalent to 11,300 tonnes) and 67% of energy was renewable
- 80% of packaging made from renewable materials (In 18/19, 70% of packaging was made from renewable materials)
- 50% of production waste is recycled (In 18/19, 32% of production was recycled)
Financial guidance 2019/20
The financial guidance for 2019/20 is unchanged at an organic revenue growth of around 4% at constant exchange rates and a reported growth in DKK of 3-4%. The EBIT margin is expected to be around 31% at constant exchange rates and in reported terms in DKK.
2019/20 has seen a negative impact on the company’s financial performance from COVID-19. Throughout the pandemic, Coloplast has had three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations. globalnewswire